S&CO Inc. Acquires 1,528 Shares of Humana Inc. (NYSE:HUM)

Key Points

• S&CO Inc. increased its shares in Humana Inc. by 7.2%, acquiring a total of 22,696 shares valued at approximately $6,005,000.
• Despite varying analyst ratings, Humana has a consensus rating of "Hold" with an average target price of $282.43.
• In its latest earnings report, Humana reported $11.58 EPS, exceeding estimates of $10.07, contributing to an 8.4% year-over-year revenue increase of $32.11 billion.

S&CO Inc. lifted its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 7.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,696 shares of the insurance provider's stock after purchasing an additional 1,528 shares during the period. S&CO Inc.'s holdings in Humana were worth $6,005,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Dodge & Cox increased its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. GAMMA Investing LLC increased its holdings in Humana by 40,881.1% during the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock worth $2,066,790,000 after buying an additional 779,193 shares during the last quarter. Southpoint Capital Advisors LP purchased a new stake in Humana during the fourth quarter worth about $190,282,000. 8 Knots Management LLC purchased a new stake in Humana during the fourth quarter worth about $145,258,000. Finally, Invesco Ltd. increased its holdings in Humana by 29.8% during the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after buying an additional 550,692 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HUM shares. Barclays set a $275.00 target price on shares of Humana and gave the stock an "equal weight" rating in a research note on Thursday. Wall Street Zen upgraded shares of Humana from a "hold" rating to a "buy" rating in a research note on Sunday, July 20th. Truist Financial reduced their target price on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research note on Wednesday, July 16th. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Sixteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $281.62.

Humana Price Performance

Humana stock traded down $2.68 during mid-day trading on Friday, hitting $247.19. 1,751,889 shares of the company traded hands, compared to its average volume of 1,749,078. Humana Inc. has a one year low of $206.87 and a one year high of $382.72. The stock has a market cap of $29.83 billion, a price-to-earnings ratio of 18.97, a price-to-earnings-growth ratio of 1.72 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.91 and a current ratio of 1.95. The stock has a fifty day moving average price of $234.64 and a 200-day moving average price of $255.48.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter in the previous year, the firm earned $6.96 earnings per share. The company's revenue for the quarter was up 9.6% compared to the same quarter last year. On average, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.